Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. More Details
Undervalued with excellent balance sheet.
Share Price & News
How has Consun Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1681 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 1681's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1681 exceeded the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: 1681 exceeded the Hong Kong Market which returned 25.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Consun Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIf You Had Bought Consun Pharmaceutical Group (HKG:1681) Stock A Year Ago, You Could Pocket A 59% Gain Today
1 month ago | Simply Wall StConsun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To CN¥0.20
1 month ago | Simply Wall StConsun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Is Consun Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1681 (HK$5.5) is trading below our estimate of fair value (HK$14.75)
Significantly Below Fair Value: 1681 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1681 is good value based on its PE Ratio (7.4x) compared to the Hong Kong Pharmaceuticals industry average (14.3x).
PE vs Market: 1681 is good value based on its PE Ratio (7.4x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: 1681 is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: 1681 is overvalued based on its PB Ratio (1.6x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Consun Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1681's forecast earnings growth (12.1% per year) is above the savings rate (1.5%).
Earnings vs Market: 1681's earnings (12.1% per year) are forecast to grow slower than the Hong Kong market (19.3% per year).
High Growth Earnings: 1681's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1681's revenue (13% per year) is forecast to grow faster than the Hong Kong market (12.7% per year).
High Growth Revenue: 1681's revenue (13% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1681's Return on Equity is forecast to be high in 3 years time (21.7%)
How has Consun Pharmaceutical Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1681 has high quality earnings.
Growing Profit Margin: 1681's current net profit margins (28.5%) are higher than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: 1681's earnings have declined by 2.3% per year over the past 5 years.
Accelerating Growth: 1681's earnings growth over the past year (526.6%) exceeds its 5-year average (-2.3% per year).
Earnings vs Industry: 1681 earnings growth over the past year (526.6%) exceeded the Pharmaceuticals industry 9.2%.
Return on Equity
High ROE: 1681's Return on Equity (19.1%) is considered low.
How is Consun Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1681's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 1681's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥101.9M).
Debt to Equity History and Analysis
Debt Level: 1681's debt to equity ratio (21.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 1681's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 1681's debt is well covered by operating cash flow (157.8%).
Interest Coverage: 1681 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Consun Pharmaceutical Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1681's dividend (5.07%) is higher than the bottom 25% of dividend payers in the Hong Kong market (1.86%).
High Dividend: 1681's dividend (5.07%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.89%).
Stability and Growth of Payments
Stable Dividend: 1681 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1681's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (38.6%), 1681's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1681's dividends in 3 years are forecast to be well covered by earnings (32.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Qian Li (55 yo)
Ms. Qian Li has been Vice Chairman and President at Consun Pharmaceutical Group Limited since November 2020. Ms. Li served as the Chief Executive Officer of Consun Pharmaceutical Group Limited (alternate n...
CEO Compensation Analysis
Compensation vs Market: Qian's total compensation ($USD2.32M) is above average for companies of similar size in the Hong Kong market ($USD300.07K).
Compensation vs Earnings: Qian's compensation has been consistent with company performance over the past year.
Experienced Management: 1681's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: 1681's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Consun Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Consun Pharmaceutical Group Limited
- Ticker: 1681
- Exchange: SEHK
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$4.401b
- Shares outstanding: 800.13m
- Website: https://www.chinaconsun.com
Number of Employees
- Consun Pharmaceutical Group Limited
- 71, Dongpeng Avenue
- Eastern section
- Guangdong Province
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/14 10:12|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.